Drugs / ICT01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05307874 | May 2022 → Oct 2025 | cancer | ImCheck Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT04243499 | Mar 2020 → Oct 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | ImCheck Therapeutics, an Ipsen company | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-13 | Ipsen | Regulatory U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia ipsen.com ↗
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-13 | Ipsen | U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia ipsen.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICT01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05307874 ↗ |
| Modality | Monoclonal antibody | “humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody” NCT04243499 ↗ |
| Route | Intravenous | “IV ICT01” NCT04243499 ↗ |